Destinations of Released Patients Following Treatment with Iodine-131 and Estimation of Doses to Members of the Public at Locations Other than Conventional Residences Receiving Such Patients
ICR 201509-3150-004 · OMB 3150-0232 · Historical Active
Destinations of Released Patients Following Treatment with Iodine-131 and Estimation of Doses to Members of the Public at Locations Other than Conventional Residences Receiving Such Patients
New collection (Request for a new OMB Control Number)
In accordance with 5 CFR 1320, the information collection is approved for three years.
Inventory as of this Action
Requested
Previously Approved
07/31/2019
36 Months From Approved
5,175
0
0
1,675
0
0
0
0
0
Although most patients return to their home after receiving diagnostic or therapeutic of Iodine-131, some patients released by the licensee may stay at another location (such as a hotel) for a few days. However, the extent of this practice is unclear. The same uncertainty exists regarding patients returning to nursing homes and other institutional settings. Therefore, one of the main objectives of this study is to obtain reliable statistical data that provides good estimates of the prevalence of these practices. The second objective is to determine, by measurements, the external and internal doses received by members of the general public at hotels, nursing homes, or other institutional settings that receive treated patients immediately after their release.
This is a new, voluntary, one-time information collection.
The data collection referred to in this OMB request is part of an NRC project, Destinations of Released Patients Following Treatment with Iodine-131, and Estimation of Doses to Members of the Public at Locations Other Than Conventional Residences Receiving Such Patients, which began October 1, 2014. Task 1, "Assess Where Patients Reside Immediately Following their Release," which is currently underway, is scheduled to conclude around February 1, 2016. Optional Task 3, which has not yet been awarded, would entail presentation of the results and conclusions of the study in the form of an NRC NUREG/CR report ("contractor report"), which would be made available to the public. In addition, it is possible that some of the results might be presented in other professional forums by the NRC contractor, subject to approval by the NRC.
$13,400
No
No
No
No
No
Uncollected
Mohammad Saba 301 415-1953
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
I-131 Patient Release Questionnaire.pdf
Destinations of I-131 patients supporting statement 6-21-16.docx
Destination of Released Patients Following Treatment with Iodine-131 and Estimation of Doses to Members of the Public at Locations Other Than Conventional Residences Receiving Such Patients